ATXI (Avenue Therapeutics) Research & Development : $7.06 Mil (TTM As of Sep. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Avenue Therapeutics Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Avenue Therapeutics's Research & Development for the three months ended in Sep. 2024 was $2.33 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Sep. 2024 was $7.06 Mil.

Avenue Therapeutics Research & Development Historical Data

The historical data trend for Avenue Therapeutics's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Avenue Therapeutics Research & Development Chart

Avenue Therapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Research & Development

Get a 7-Day Free Trial

23.19

2.87

1.25

2.70

10.36

Avenue Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Research & Development	Get a 7-Day Free Trial															0.91	0.98	2.39	1.36	2.33

Avenue Therapeutics Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $7.06 Mil.

Avenue Therapeutics (NAS:ATXI) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Avenue Therapeutics Research & Development Related Terms

Thank you for viewing the detailed overview of Avenue Therapeutics's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

Avenue Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Avenue Therapeutics Inc (NAS:ATXI) » Definitions » Research & Development

Comparable Companies

Traded in Other Exchanges

49Y:Germany

Address

1111 Kane Concourse, Suite 301, Bay Harbor Islands, FL, USA, 33154

Website

https://www.avenuetx.com

Avenue Therapeutics Inc is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of rare and neurologic diseases. It focuses on developing its product candidate, AJ201, for spinal and bulbar muscular atrophy, BAER-101, for the treatment of epilepsy and panic disorders, and IV Tramadol for the management of moderate-to-moderately-severe pain in adults.

Executives

Neil Herskowitz	director	2109 BROADWAY, SUITE 206, NEW YORK NY 10023
Jay D Kranzler	director	4350 EXECUTIVE DRIVE, SUITE 325, SAN DIEGO CA 92121
Rosenwald Lindsay A Md	director	375 PARK AVE, NEW YORK NY 10152
Fortress Biotech, Inc.	10 percent owner	1111 KANE CONCOURSE, SUITE 301, BAY HARBOR ISLANDS FL 33154
Invagen Pharmaceuticals, Inc.	10 percent owner	SITE B, 7 OSER AVE., HAUPPAUGE NY 11788
Alexandra Maclean	officer: Chief Executive Officer	C/O AVENUE THERAPEUTICS, INC., 2 GANSEVOORT STREET, 9TH FLOOR, NEW YORK NC 10014
Faith L. Charles	director	ABEONA THERAPEUTICS INC., 1330 AVENUE OF THE AMERICAS - FLOOR 33, NEW YORK NY 10019
David Jin	officer: Int. PEO, Int. PFO, and COO	C/O AVENUE THERAPEUTICS, INC., 1140 AVENUE OF THE AMERICAS, FLOOR 9, NEW YORK NY 10036
Joseph Walter Vazzano	officer: Chief Financial Officer	1330 AVENUE OF THE AMERICAS, 33RD FLOOR, NEW YORK NY 10019
Curtis Gale Oltmans	director	C/O ARRAY BIOPHARMA INC., 3200 WALNUT ST., BOULDER CO 80301
Lucy Lu	director, officer: President, CEO	THE FEMALE HEALTH COMPANY, 4400 BISCAYNE BOULEVARD, SUITE 888, MIAMI FL 33137
Elizabeth Garrett Ingram	director	30930 RUSSELL RANCH ROAD, WESTLAKE VILLAGE CA 91362
Thomas Gregory Moore	director	C/O AKORN, INC., 1925 WEST FIELD COURT, SUITE 300, LAKE FOREST IL 60045
Nishant Saxena	director	CIPLA HOUSE, PENINSULA BUSINESS PARK, LOWER PAREL, MUMBAI K7 400013
Jaideep Ashok Gogtay	director	CIPLA LTD., MUMBA CENTRAL, BESIDE CITY CENTER, MUMBAI K7 400008